@FiercePharma: ICYMI: Suit says CVS manipulated generic drug prices. Item | Follow @FiercePharma
@EricPFierce: As #Hospira expands recall of #ketorolac to 37M vials you've got to wonder what Pfizer thinks. Article | Follow @EricPFierce
@CarlyHFierce: #ICYMI Friday: Ackman's 'wolf pack' drove Allergan into foreign hands, former CEO says. More | Follow @CarlyHFierce
> Teva Pharmaceutical Industries ($TEVA) lined up more than $30 billion in financing for its $40 billion buyout of Allergan's ($AGN) generics business, with 11 lenders committing to the deal. Report
> Hetero Pharma rolled out its biosimilar version of Roche's ($RHHBY) Rituxan in India, under the brand name Maball; it will compete with versions from Dr. Reddy's Laboratories and Intas. Release
> Gilead Sciences' ($GILD) hepatitis C sales growth may be slowing, but with more than 2 million patients still untreated in the U.S., it's not going to run out of new business anytime soon. Report
> European regulators recommended Novartis' ($NVS) Revolade to treat severe aplastic anemia who haven't responded to immunosuppressive therapy. Report
> Citing the risk of hacking, the FDA recommended that hospitals stop using Hospira's ($HSP) Symbiq medication infusion pump. Report
Medical Device News
@FierceMedDev: ICYMI Friday: Upstart gets $6M to back the first FDA-cleared, OTC conception assistance device. Article | Follow @FierceMedDev
@VarunSaxena2: ResMed acquires China's Curative Medical to get bigger in sleep disorder devices. Item | Follow @VarunSaxena2
@EmilyWFierce: $OSUR got an FDA OK for emergency use of its rapid Ebola test. Press release | Follow @EmilyWFierce
> U.S. Army scientists roll out innovative blood loss monitor device. More
> Bard gets additional CMS reimbursement for its drug-coated angioplasty balloon. Story
Biotech News
@FierceBiotech: ICYMI Friday: Merck's Ebola vaccine is 100% successful in interim Phase III results. Report | Follow @FierceBiotech
@JohnCFierce: Is it just me, or is $SHPG's Ornskov overrated? Shire chief Ornskov bets $300M on another eye drug bolt-on buyout. Story | Follow @JohnCFierce
@DamianFierce: Charming addition to the drug co. nonsense lexicon: "biobetter." More | Follow @DamianFierce
> Sorrento buys into biosimilars with a Chinese antibody deal. Report
> Lexicon rockets up after a positive PhIII study sets up an NDA. Story
> AstraZeneca deepens its Isis ties with a $65M R&D pact. Article
Animal Health News
> VCA ups 2015 guidance as Q2 sales and profits soar past expectations. More
> Heska doubles Q2 operating income but misses on revenue. Report
> Schein misses Q2 estimates on currency woes and sales challenges. Story
> IDEXX shares climb on record diagnostics placements and Q2 earnings gain. Article
> Report: 'Precision farming' set to revolutionize livestock care. More
Biotech IT News
> Y Combinator continues push into bioinformatics with investment in Cofactor Genomics. News
> NIH to bankroll initiatives to build Cancer Genomics Cloud Pilots into R&D programs. Report
> Ex-BGI CEO's next move? A $1.6B push to find a 'formula for life.' More
> First startups graduate from Illumina Accelerator as deadline for next phase nears. Story
> Venter's HLI plans to ramp up sequencing capacity as more pharma deals near fruition. Article
Pharma Marketing News
> Express Scripts kicks another batch of meds off its preferred formulary. Item
> Pfizer's hot-selling Ibrance gets even hotter with new $710M sales estimate for 2015. News
> Sanofi and MannKind launch Afrezza DTC ad campaign in stealth mode. Story
> Shyft Analytics: Targeted drugs need a data-fueled marketing shift. Article
> Can a dwindling rep tally keep Vivus' obesity med in the game? More
And Finally ... The value of the Type 2 diabetes market is expected to hit $39 billion by 2021. Report